Articles

Comparison Study between Orlistat and Moringa Oleifera as an Appetite Suppressant in Case of Obese Patients

/in /by

Obesity is a disease in which excess accumulation of fat occurs in the adipose tissues of the body. Obesity is the main cause of many diseases such as type- 2 diabetes, cardiovascular diseases, and mental health disorders such as depression.  In recent studies, Moringa oleifera have been found to have antilipidemic activity by reducing the levels of total cholesterol, triglycerides and low density lipoprotein. This review compares the therapeutic effect of herbal drug to orlistat, a lipase inhibitor. The mechanism of action of Orlistat is to prevent the intestinal absorption of fat present in food resulting into excretion of the unabsorbed fat from the body in the stool.

Surgical Treatment of Gallstones in Patients Undergoing Gastric Bypass Surgery as a Treatment of Obesity

/in /by

Introduction: Sustained weight loss after gastric bypass is achieved by a combination of gastric restriction and a variable degree of malabsortion and has therefore a greater risk for gallstone development than purely restrictive procedures like adjustable gastric banding.

Objectives: The main objective of the study is to analyse the surgical treatment of gallstones in patients undergoing gastric bypass surgery as a treatment of obesity.

Material and methods: This randomized control trial was conducted in Jinnah Hospital, Lahore during 2021 to 2022. Patients who underwent bariatric surgery for obesity were included in the study. Those who had cholecystectomy before bariatric surgery, those who underwent concomitant cholecystectomy (CC) during bariatric surgery, those with concomittant gall stoness and those who did not attend their follow-up regularly were excluded from the study.

Results: The data was collected from 100 patients and we reviewed records from all patients treated for acute biliary pancreatitis. The average age was 36.43±9.52 years and, the ratio of women/men was 151 (81.6%)/34 (18.4%). Mean BMI was determined as 44.16±5.09. When comorbidities were evaluated, 116 (62.7%) patients had comorbidity, while 69 (37.3%) patients did not. Conclusion: It is concluded that prophylactic and selective management can be safely performed and the only significant difference with patients not submitted to concomitant cholecystectomy is mostly observed in operative times that are higher in those who do undergo cholecystectomy.